Thiotepa–busulfan–fludarabine (TBF) conditioning regimen in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis: an outcome analysis from the Chronic Malignancies Working Party of the EBMT
Giorgia Battipaglia, Katya Mauff, Lotus Wendel, Emanuele Angelucci, Mohamad Mohty, William Arcese, Stella Santarone, Marie Thérèse Rubio, Nicolaus Kröger, María Laura Fox, Didier Blaise, Anna Paola Iori, Renato Fanin, Yves Chalandon, Pietro Pioltelli, Giuseppe Marotta, Patrizia Chiusolo, Matjaž Sever, Carlos Solano, Nathalie Contentin, Liesbeth C. de Wreede, Tomasz Czerw, Juan Carlos Hernández‐Boluda, Patrick Hayden, Donal P. McLornan, Ibrahim Yakoub‐Agha
Topics & Concepts
MedicineBusulfanThioTEPAFludarabineRegimenInternal medicineTransplantationHematopoietic stem cell transplantationSurgeryGastroenterologyGraft-versus-host diseaseMyelofibrosisOncologyCyclophosphamideChemotherapyBone marrowMyeloproliferative Neoplasms: Diagnosis and TreatmentEosinophilic Disorders and SyndromesChronic Myeloid Leukemia Treatments